ES2549690B1 - Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz - Google Patents

Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz Download PDF

Info

Publication number
ES2549690B1
ES2549690B1 ES201300887A ES201300887A ES2549690B1 ES 2549690 B1 ES2549690 B1 ES 2549690B1 ES 201300887 A ES201300887 A ES 201300887A ES 201300887 A ES201300887 A ES 201300887A ES 2549690 B1 ES2549690 B1 ES 2549690B1
Authority
ES
Spain
Prior art keywords
high specificity
modified antibodies
multipurpose
highly safe
production
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201300887A
Other languages
English (en)
Other versions
ES2549690B8 (es
ES2549690A2 (es
ES2549690R1 (es
Inventor
Juan LÓPEZ DE SILANES PÉREZ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INOSAN BIOPHARMA S A
Inosan Biopharma Sa
Original Assignee
INOSAN BIOPHARMA S A
Inosan Biopharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INOSAN BIOPHARMA S A, Inosan Biopharma Sa filed Critical INOSAN BIOPHARMA S A
Publication of ES2549690A2 publication Critical patent/ES2549690A2/es
Publication of ES2549690R1 publication Critical patent/ES2549690R1/es
Application granted granted Critical
Publication of ES2549690B1 publication Critical patent/ES2549690B1/es
Publication of ES2549690B8 publication Critical patent/ES2549690B8/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz.#La invención se relaciona con la producción y desarrollo de una formulación inyectable liofilizada de anticuerpos modificados o variantes de ellos, altamente específicos neutralizantes de mezclas heterólogas de proteínas, péptidos y otros componentes orgánicos e inorgánicos que tienen diferentes actividades específicas y pueden incluir pero no se limitan a venenos de animales ponzoñosos. Por conveniencia haremos referencia a venenos, pero se incluyen todo tipo de venenos de animales terrestres y marinos. También está dirigida al método de producción que incluye la hiperinmunización de mamíferos para la producción de anticuerpos altamente específicos, el proceso de modificación (fragmentación) y purificación, y finalmente la formulación inyectable liofilizada, que le confiere propiedades de alta pureza y alta especificidad.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
    imagen2
ES201300887A 2012-10-18 2013-09-27 Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz Active ES2549690B8 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
MX2012012132A MX367136B (es) 2012-10-18 2012-10-18 Proceso para purificar fragmentos de anticuerpos polivalentes derivados de plasma hiperinmune.
MX/A/2012/012132 2012-10-18

Publications (4)

Publication Number Publication Date
ES2549690A2 ES2549690A2 (es) 2015-10-30
ES2549690R1 ES2549690R1 (es) 2016-01-11
ES2549690B1 true ES2549690B1 (es) 2016-09-21
ES2549690B8 ES2549690B8 (es) 2018-06-21

Family

ID=50097480

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201300887A Active ES2549690B8 (es) 2012-10-18 2013-09-27 Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz

Country Status (4)

Country Link
US (2) US10538577B2 (es)
ES (1) ES2549690B8 (es)
FR (1) FR2997084A1 (es)
MX (1) MX367136B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2019015360A (es) 2017-10-02 2020-02-07 Laboratorios Silanes S A De C V Proceso de alto rendimiento para la produccion de antivenenos de fragmentos f(ab')2 de anticuerpos.

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2065196A (en) 1934-10-09 1936-12-22 Parfentjev Ivan Alexandrovich Method for purification of antitoxins and the like
US2123198A (en) 1936-10-23 1938-07-12 Lederle Lab Inc Treatment of antitoxins and the like
US2175090A (en) 1938-06-22 1939-10-03 Lederie Lab Inc Purification of antibody compositions
US4849352A (en) 1984-10-09 1989-07-18 Sullivan John B Antibody purification process
US6193969B1 (en) 1993-06-03 2001-02-27 Protherics Inc. Antibody fragments in therapy
IN188098B (es) 2000-03-09 2002-08-17 Serum Inst India Ltd
US6709655B2 (en) 2001-02-28 2004-03-23 Instituto Bioclon, S.A. De C.V. Pharmaceutical composition of F(ab1)2 antibody fragments and a process for the preparation thereof
US7179458B2 (en) 2002-03-08 2007-02-20 Osel, Inc. Lactobacilli expressing biologically active polypeptides and uses thereof
WO2005009464A1 (en) 2003-07-25 2005-02-03 Lopez De Silanes Juan Administration of anti-cytokine f(ab')2 antibody fragments
MXPA04008435A (es) 2004-08-31 2006-03-02 Univ Mexico Nacional Autonoma Inmunogeno y anti-veneno contra el veneno de la arana violinista.
MXPA06003717A (es) 2006-04-03 2006-09-29 Silanes Sa De Cv Lab Composiciones oftalmicas de proteinas inhibidoras de citocinas implicadas en procesos inflamatorios o inmunologicos.
CN101816789B (zh) 2010-04-08 2012-09-05 成都军区疾病预防控制中心军事医学研究所 抗蝰蛇蛇毒冻干血清及制备方法

Also Published As

Publication number Publication date
ES2549690B8 (es) 2018-06-21
FR2997084A1 (fr) 2014-04-25
US20160368969A1 (en) 2016-12-22
US10538577B2 (en) 2020-01-21
ES2549690A2 (es) 2015-10-30
MX367136B (es) 2019-08-06
ES2549690R1 (es) 2016-01-11
US20200190166A1 (en) 2020-06-18
MX2012012132A (es) 2013-12-08

Similar Documents

Publication Publication Date Title
PH12017501287A1 (en) A novel complex comprising a cell penetrating peptide, a cargo and a tlr peptide agonist
AR107290A1 (es) ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS
NZ734919A (en) Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
CL2015000420A1 (es) Anticuerpo de unión a gfr alfa 3 (gfra3); ácido nucleico que lo codifica; vector; método para producirlo; composición farmacéutica que lo comprende; y uso para tratar una afección o enfermedad relacionada con gfra3.
CL2013001673A1 (es) Composicion acuosa que comprende aproximadamente 18% p/v de concentracion, donde al menos el 95% de las proteinas son igg; metodo mejorado para preparar dicha composición.
BR112013005136A2 (pt) composições e métodos para controlar pragas de nematodeo
UY36157A (es) Composiciones pesticidas y procedimientos relacionados con las mismas
NZ728484A (en) Molecules having certain pesticidal utilities, and intermediates, compositions, and processes related thereto
NZ731103A (en) Molecules having pesticidal utility, and intermediates, compositions, and processes, related thereto
WO2014020129A3 (en) Allatostatin-b peptides for inducing the settlement of lophotrochozoan marine larvae
WO2013001285A3 (en) Fmdv vp1 peptides
DOP2012000232A (es) Proteínas de unión a antigeno especificas para el componente amiloide serico p
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
BR112015008972A2 (pt) vacina para prevenir doença de edema em suínos
WO2014153168A3 (en) Porcine astrovirus sequences and uses thereof
ES2549690B1 (es) Inmunoterapéuticos polivalentes de alta especificidad basados en anticuerpos modificados y formulación liofilizada inyectable altamente segura y eficaz
PH12015502072B1 (en) Nutritional compositions containing a peptide component and uses thereof
MX2016009747A (es) Vacunas contra el reovirus aviar.
WO2014111840A3 (en) Peptide
AR092102A1 (es) Hidrolizado de proteinas
ES2441880B1 (es) Composición basada en polipéptidos para el tratamiento de miasis
ES2609993B1 (es) Péptido para el tratamiento de la alergia
ES2551808B1 (es) Uso de vitamina E para proteger a los peces de la intoxicación por Cilindrospermopsina
TH174503A (th) โมเลกุลที่ใช้ประโยชน์เป็นสารที่มีฤกธิ์ฆ่าศัตรูพืชและสัตว์, แเละสารมัธยันตร์, องค์ประกอบ, และ กรรมวิธีที่เกี่ยวข้องกับมัน
Gezer et al. Wood destroyer macrofungi of Denizli (Turkey) region

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2549690

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20160921